非小細胞肺がん治療薬S-488410の第II相臨床試験

基本情報

NCT ID: NCT01592617
ステータス: 不明
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 45
治験依頼者名: Shiga University

概要

The investigators identified three cancer-testis antigens, as targets for cancer vaccination against lung cancer. In this clinical study, the investigators examine using a combination of three peptides from these three antigens (S-488410) the safety, immunogenicity, and antitumor effect of vaccine treatment for advanced non-small cell lung cancer patients.

対象疾患

Carcinoma, Non-Small-Cell Lung

介入

S-488410(DRUG)

依頼者（Sponsor）

Tokyo University(OTHER)

Tohoku University(OTHER)

Fukushima Medical University(OTHER)

Shiga University(OTHER)

Showa University(OTHER)

塩野義製薬株式会社(INDUSTRY)

University Of Chicago(OTHER)

実施施設 (1)

滋賀医科大学医学部附属病院

Ōtsu, Shiga, Japan